Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

7.95EUR
11 Jul 2014
Price Change (% chg)

€-0.25 (-3.05%)
Prev Close
€8.20
Open
€8.14
Day's High
€8.47
Day's Low
€7.90
Volume
472,560
Avg. Vol
858,304
52-wk High
€12.30
52-wk Low
€2.24

IPH.PA

Chart for IPH.PA

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 0.69
Market Cap (Mil.): €421.07
Shares Outstanding (Mil.): 52.97
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): -- 102.68 35.77
EPS (TTM): -0.08 -- --
ROI: -7.27 -0.70 18.27
ROE: -9.09 -1.57 19.16
Search Stocks

BRIEF-Innate Pharma buys rights to drug from Novo Nordisk

Feb 5 - Innate Pharma SA : * Buys full rights to anti-nkg2a checkpoint inhibitor from Novo Nordisk

05 Feb 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks